Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Immunotherapies have shown little efficacy in brain cancers due to their inability to cross the blood-brain barrier. Now, however, researchers have developed a new nanotechnology approach that allowed immune ... Read more
A new study suggests that tumors with more mutations respond better to immunotherapy. But determining what constitutes a “high” number of mutations in a given tumor type, and implementing ... Read more
Most neurofibromatosis type 1 (NF1) patients with slow-growing brain tumors contain high numbers of tumor-killing immune cells, making them likely to respond to immunotherapies, a global study suggests. The study, “The ... Read more
Obesity is known to promote cancer, but, paradoxically, obese cancer patients may respond better to cancer immunotherapy, a recent study has found. The study, “Paradoxical effects of obesity on ... Read more
Pin It on Pinterest